Cell Therapy in Dilated Cardiomyopathy: Observational Study

Ministry of Health, Brazil24 enrolled

Overview

Using bone marrow mononuclear cell in 24 patients with Idiopathic dilated cardiomyopathy

Patients with Idiopathic dilated cardiomyopathy class II to IV NYHA with ejection fraction \<35% were selected for phase I clinical trial of bone marrow mononuclear cell delivery in the coronary arteries and followed for 6 months

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cardiomyopathy, Dilated

Interventions

Cell therapyOTHER

bone marrow mononuclear cell

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of idiopathic dilated cardiomyopathy * Optimized therapy and for idiopathic dilated cardiomyopathy * Left ventricular ejection fraction (Simpson) \< 35% * Peak oxygen consumption (VO2 peak) \< 16 mL.kg-1min-1 * Functional classes II-IV of the NYHA Exclusion Criteria: * dilated cardiopathies of ischemic or chagasic origin * primary valve disease * excessive use of alcohol or illicit drugs * pregnancy * ventricular arrhythmias * any co-morbidity with impact on survival

Locations (1)

INCL - National Institute of Cardiology Laranjeiras

Rio de Janeiro, Rio de Janeiro, Brazil

Outcomes

Primary Outcomes

echocardiography

Time frame: 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.